# S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

> **NCT00445848** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 89 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride

## Key facts

- **NCT ID:** NCT00445848
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2013-08
- **Final completion:** 2014-01
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2020-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445848, "S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00445848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*